John Lepore, MD, CEO of ProFound Therapeutics, explore how multiomics, combined with artificial intelligence and real-world data is advancing drug discovery. The drug discovery landscape is undergoing a transformative shift, driven by the growing demand for precision medicine and tremendous technological advances that inform systems biology. Traditional R&D approaches that rely on single -omics data, […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!